Palbociclib

Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib is a highly specific inhibitor of cyclindependent kinase 4 (Cdk4) (IC50, 0.011 μmol/L) and Cdk6 (IC50, 0.016 μmol/L), having no activity against a panel of 36 additional protein kinases.

外观：黄色至灰白色晶状固体

分子量 : 447.53

分子式: C24H29N7O2

CAS号: 571190-30-2

溶剂/溶解度 : DMSO

晶型：2种，A和B，均为无水晶体

储存条件: 参考Co^[1]A中推荐的条件进行储存。

发起人状况开始日期结束日期阶段最后更改日期Pfizer IncMetastatic breast cancer28-FEB-1331-MAR-15Phase 3 Clinical15-NOV-13German Breast GroupBreast tumor31-OCT-1330-NOV-21Phase 3 Clinical12-SEP-13Institut BergonieGastrointestinal stromal tumor31-AUG-1331-AUG-15Phase 2 Clinical12-SEP-13Washington University in St LouisBreast tumor30-JUN-1331-AUG-15Phase 2 Clinical21-JUN-13Pfizer IncMetastatic breast cancer30-SEP-1331-JAN-17Phase 3 Clinical01-NOV-13